ZYME - Zymeworks Inc.
| Previous close | 35.88 |
| Open | 35.68 |
| Bid | 33.58 x 800 |
| Ask | 33.81 x 900 |
| Day's range | 32.17 - 35.88 |
| 52-week range | 14.65 - 52.75 |
| Volume | 206,812 |
| Avg. volume | 472,293 |
| Market cap | 1.528B |
| Beta (5Y monthly) | 1.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.83 |
| Earnings date | 01 Mar 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 24.88 |
- Business Wire
Zymeworks Appoints Dr. Kelvin Neu to the Board of Directors
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Kelvin Neu, M.D., to its Board of Directors.
- Zacks
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -97.62% and -79.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Zymeworks Reports 2019 Year-End Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2019.
- Zacks
Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Zymeworks to Present at Raymond James 41st Annual Institutional Investors Conference
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Raymond James Institutional Investors Conference taking place March 1-4, 2020 in Orlando, FL.
- Zacks
Zymeworks Inc. (ZYME) Reports Q3 Loss, Tops Revenue Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -1.45% and 1.22%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Earnings Preview: Zymeworks Inc. (ZYME) Q3 Earnings Expected to Decline
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Zymeworks Inc. (ZYME) Reports Q2 Loss, Tops Revenue Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -10.91% and 8.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
